Extent of metallothionein expression in correlation with expression of Ki-67 antigen in soft tissue fibrosarcomas in dogs

• Autorzy: Nowak M , Madej J.A. , Dziegiel P.
• Języki publikacji: EN

Abstrakty

EN

This study is aimed at a immunocytochemical demonstration of metallothionein and Ki-67 expression, and to define the correlation between the markers in spontaneous fibrosarcomas in dogs. Material for the study was sampled during operative procedures from 27 dogs of various breeds, aging 5 to 16 years. The neoplastic tumours were histopathologically verified and immunohistochemical reactions were conducted to detect MT and Ki-67. Microphotographs of the preparations were subjected to computer-assisted image analysis. In light of the numerous established studies for a high prognostic value of Ki-67, for this reason we have identified in our studies a weak correlation between the expressions of MT and Ki-67 (r = 0.15), which allows us to conclude that the presence of metallothioneins in the cells of soft tissue fibrosarcomas in dogs does not manifest an unequivocal relationship with augmented proliferative potential of tumour cells, as it was demonstrated in similar tumours in humans.

Słowa kluczowe

EN

veterinary medicine; fibrosarcoma; dog; pathophysiology; Ki-67 protein; metallothionein expression

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2007
• Tom: 51
• Numer: 1
• Opis fizyczny: p.139-144,fig.,ref.

Twórcy

autor

Nowak M

• Wroclaw University of Environmental and Life Sciences, 50-375 Wroclaw, Poland

autor

Madej J.A.

autor

Dziegiel P.

Bibliografia

• 1. Baez J L., Hendrick M.J., Szofer F S., Goldkamp D., Sorenmo K.U.: Liposarcomas in dogs: 56 cases (1989- 2000). J Am Vet Med Assoc 2004, 224, 887-891.
• 2. Barnard N.J., Hall P.A., Lemoine N.R., Kadarr N.: Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987, 152, 287-295.
• 3. Beyersmann D., Haase H.: Functions of zinc in signalling, proliferation, and differentiation of mammalian cells. BioMetals 2001, 14, 331-341.
• 4. Boon-Huat B., Jin R., Jayasurya A.: Analysis of metallothionein expression in human cancers. Acta Histochem Cytochem 2001, 34, 171-176.
• 5. Brown D.C., Gatter K.C.: Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990, 17, 489- 503.
• 6. Cai L., Koropatnick J., Cherian M.G.: Metallothionein protects DNA from copper-induced but not iron-induced cleavage in vitro. Chem Biol Interact 1995, 96, 143-155.
• 7. Cai L., Satoh M., Tohyama C., Cherian M.G.: Metallothionein in radiation exposure: its induction and protective role. Toxicology 1999, 132, 85-98.
• 8. Cherian M.G., Apostolova M.D.: Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol 2000, 46, 347-356.
• 9. Coyle P., Philcox J.C., Carey L.C., Rofe A.M.: Metallothionein: the multipurpose protein. Cell Mol Life Sci 2002, 59, 627-647.
• 10. Dincer Z., Jasani B., Haywood S., Mullins J.E., Funtealba I.C.: Metallothionein expression in canine and feline mammary and melanotic tumours. J Comp Pathol 2001, 125, 130-136.
• 11. Dzięgiel P., Forgacz J., Suder E., Surowiak P., Kornafel J., Zabel M.: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 2003, 18, 401-407.
• 12. Dzięgiel P., Salwa-Zurawska W., Zurawski J., Wojnar A., Zabel M.: Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 2005, 20, 83-89.
• 13. Dzięgiel P., Suder E., Surowiak P., Kornafel J., Zabel M.: Expression of metallothionein in synovial sarcoma cells. Appl Immunohistochem Mol Morphol 2002, 10, 357-362.
• 14. Dzięgiel P.: Expression of metallothioneins in tumour cells. Pol J Pathol 2004, 55, 3-12.
• 15. Gaumann A., Tews D.S., Mentzel T., Petrow P.K., Mayer E., Otto M., Kirkpatrick C.J., Kriegsmann J.: Expression of drug resistance related proteins in sarcomas of pulmonary artery and poorly differentiated leiomyosarcomas other origin. Virchows Arch 2003, 442, 529-537.
• 16. Gerdes J., Shwab U., Lemke H., Baisch H., Wacker H.H.: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated witch cell proliferation. Int J Cane 1983, 31, 13-20.
• 17. Giziński S., Boryczko Z., Katkiewicz M., Bostedt H.: Ki- 67 protein as a prognostic factor in mammary gland tumors in female dogs. Medycyna Wet 2003, 59, 888- 891.
• 18. Jensen V., Sorensen F.B., Bentzen S.M., Ladekarl M., Nielsen O.S., Keller J., Jensen O.M.: Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology 1998, 32, 536-546..
• 19. Jin R., Bay B.H., Chow V.T., Tan P.H.: Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat 2001, 66, 265-272.
• 20. Jin R., Chow V.T., Tan P.H, Dheen S.T., Duan W., Bay B.H.: Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002, 23, 81-86.
• 21. Kotoh S., Naito S., Sakamoto N., Goto K., Kumazawa J.: Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J Urol 1994, 152, 1267-1270.
• 22. Nakano M., Sogawa C.A., Sogawa N., Mishima K., Yamachika E., Mizukawa N., Fukunaga J., Kawanoto T., Sawaki K., Sugahara T., Furuta H.: Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. Anticancer Res 2003, 23, 299-303.
• 23. Nowak M., Madej J.A.: Prevalence of neoplasms in domestic animals in Lower Silesia between 2000-2004. Medycyna Wet 2006, 62, 900-904.
• 24. Nowak M., Madej J.A., Dzięgiel P.: Expression of metallothionein and its correlation with Ki-67 antigen in bitch's mammary gland adenocarcinomas. Medycyna Wet 2006, 62, 427-431.
• 25. Paraskevakou H., Theocharis S.E., Tseleni S., Athanasiades A., Davaris P.S.: Expression of metallothionein in renal cell carcinoma: an immunohistochemical study. Lab Invest 1999, 79, 103.
• 26. Remmele W., Stegner H.E.: Vorschlag zur einheitlichen Definition eines immunoreaktiven Score (IRS) für den immunohistochemischen Oestrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie 1987, 8, 138-140.
• 27. Sapierzyński R., Sapierzyńska E.: Nowotwory mezenchymalne skóry i tkanki podskórnej u psów i kotów. Życie wet 2004, 79, 488-492.
• 28. Shukla V.K., Aryya N.C., Pitale A., Pandey M., Dixit V.K., Reddy C.D., Gautam A.: Metallothionein expression in carcinoma of the gallbladder. Histopathology 1998, 33, 154-157.
• 29. Simpkins C.O.: Metallothionein in human disease. Cell Mol Biol 2000, 46, 465-488.
• 30. Surowiak P., Dzięgiel P., Matkowski R., Kornafel J., Wojnar A., Zabel M.: Immunocytochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7-years course of the disease. Folia Histochem Cytobiol 2002, 40, 199-200.
• 31. Trieb K., Kotz R.: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 2001, 33, 11-17.
• 32. Vašák M., Hasler D.W.: Metallothioneins: new functional and structural insights. Curr Opin Chem Biol 2000, 4, 177-183.
• 33. Weiss S.W., Goldblum J.R.: Soft tissue tumours. Ed. Mosby, St.Louis, London, Philadelphia, Sydney, Toronto 2001.